

Pain-relieving plaster for the treatment of knee osteoarthritis: a multi-center, randomized, positive drug parallel-controlled clinical trial

Submission date 18/09/2024	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 27/09/2024	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 29/11/2024	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Knee osteoarthritis (KOA) is a chronic degenerative joint disease clinically manifested by knee pain, swelling, malformation, and limited mobility. Currently, non-surgical therapies are the first-line treatment for most patients with mild to moderate KOA, effectively alleviating pain symptoms and improving functional activities. These therapies include oral administration of acetaminophen, topical application of nonsteroidal anti-inflammatory drugs, or intra-articular injection of corticosteroids and hyaluronic acid. Pain-Relieving Plaster is a topical Tibetan medicinal plaster primarily composed of herbs such as *Lamiophlomis rotata* and *Curcuma longa*, with anti-inflammatory, blood circulation-improving, multi-target analgesic, and tissue damage repair-promoting effects. Previous clinical studies have suggested the potential positive effects of Pain-Relieving Plaster in treating KOA. The objectives of this study are to investigate and explore the efficacy and safety of Pain-Relieving Plaster in treating KOA.

Who can participate?

Patients aged between 40 and 75 years with KOA

What does the study involve?

This is an interventional study where participants will be randomly assigned to two groups in a 1:1 ratio: the experimental group and the control group. Both participants and researchers cannot preselect the group assignment. The experimental group will use Pain-Relieving Plaster (applied for 8 hours per patch, one patch per morning), while the control group will use Flurbiprofen Cataplasms (applied for 8 hours per patch, one patch in the morning and one before bedtime). The study will evaluate the effectiveness of the interventions using clinical scoring, health-related quality of life, knee circumference, and knee range of motion. Safety will be evaluated using laboratory test results, records of adverse events, and records of the severity of local skin reactions at the application site. Additionally, evaluations of patient compliance, application status, concomitant medications, and emergency management will be conducted.

What are the possible benefits and risks of participating?

Participating in this study may lead to an improvement in the participant's condition, and they

will receive attentive medical care. Their participation may help doctors gain more insights into KAO, Pain-Relieving Plaster, and Flurbiprofen Cataplasms, potentially benefiting future patients with the same or similar conditions.

Known adverse reactions of Pain-Relieving Plaster identified in previous studies and clinical applications include:

1. According to the product instructions, patients with an allergic constitution may experience allergic reactions to the adhesive tape or drug-contact itching, and even develop redness, swelling, or blisters.
2. Based on literature research results and surveys of clinicians and patients, Pain-Relieving Plaster does not have systemic adverse reactions; occasional local skin adverse reactions are mainly irritant contact dermatitis, including local itching, erythema, and papules, with rare occurrences of local blisters, pigmentation, and skin ulceration. The majority of adverse reactions occur at sites where the adhesive tape directly contacts the skin, possibly related to skin irritation caused by the tape.

Adverse reactions identified in similar drugs include:

1. Allergic reactions
2. Skin damage
3. Drug irritation

Known adverse reactions of Flurbiprofen Cataplasms identified in previous studies and clinical applications include:

1. Severe adverse reactions can induce asthma (aspirin-induced asthma): As it may induce asthma (frequency unknown), use should be discontinued if initial symptoms such as respiratory abnormalities or dyspnea occur. Furthermore, asthma induced by this product may appear several hours after application.
2. Other adverse skin reactions include itching (1.16%), redness (1.12%), rash (0.1% to less than 5%), macules, pain, etc., each occurring at a frequency of 0.1% or less.

Where is the study run from?

Peking Union Medical College Hospital, China

When is the study starting and how long is it expected to run for?

August 2024 to September 2026

Who is funding the study?

Tibet Cheezheng Tibetan Medicine Co., Ltd. (China)

Who is the main contact?

Prof. Jianping Liu, liujp@bucm.edu.cn

Contact information

Type(s)

Public, Principal investigator

Contact name

Prof Xisheng Weng

Contact details

Peking Union Medical College Hospital, No.1 Shuaifuyuan, Dongcheng District
Beijing
China
100730
+86 010 - 69152712
drwengxsh@163.com

Type(s)

Scientific

Contact name

Prof Jianping Liu

ORCID ID

<https://orcid.org/0000-0002-0320-061X>

Contact details

Centre for Evidence-Based Chinese Medicine
Beijing University of Chinese Medicine
No. 11 Bei San Huan Dong Lu
Chaoyang District
Beijing
China
100029
+86 (0)10 64286760
liujp@bucm.edu.cn

Additional identifiers

Protocol serial number

20240605V1.0

Study information

Scientific Title

Pain-relieving plaster versus flurbiprofen cataplasms in terms of pain, stiffness, functional activities, joint swelling, quality of life, and safety for knee osteoarthritis treatment: a multi-center, randomized, controlled, non-inferiority clinical trial.

Acronym

PEP

Study objectives

In terms of alleviating pain and stiffness, improving functional activities, reducing joint swelling, and enhancing quality of life, and safety, Pain-Relieving Plasters are not inferior to Flurbiprofen Cataplasms.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 05/08/2024, Ethics Review Committee of the Chinese Academy of Medical Sciences and Peking Union Medical College Hospital (No.1 Shuaifuyuan, Dongcheng District, Beijing, Beijing, 100730, China; +86 010-69156874; pumchkyc@126.com), ref: I-24PJ1637

Study design

Multicenter randomized active-controlled non-inferiority trial design

Primary study design

Interventional

Study type(s)

Quality of life, Treatment, Safety, Efficacy

Health condition(s) or problem(s) studied

Knee osteoarthritis

Interventions

Professional statisticians will use SAS software to generate a random number sequence and its "central code assignment" (to specify the range of treatment codes assigned to each research center) according to the blocked randomization method. Within each center, subjects will be assigned a subject number based on the chronological order of their entry into the study (determined by the random number sequence and its "central code assignment"), that is, subjects with knee osteoarthritis are randomly assigned to the experimental group (pain-relieving plaster) and the control group (Flurbiprofen Cataplasms) in a 1:1 ratio.

Allocation concealment will be achieved using sequentially coded, sealed, opaque envelopes. Personnel unrelated to the study will be responsible for allocating and packaging the study medications. Clinicians recruited subjects, and those who met the inclusion criteria and did not meet any of the exclusion criteria will be given the corresponding medication by dedicated researchers after signing the informed consent form.

Before treatment, the patient's basic information will be recorded, and a physical examination, blood routine test, and urine routine test will be conducted. Women of childbearing age will undergo a blood pregnancy test to rule out pregnancy. Liver function tests (including ALT, AST, ALP, TBIL, γ -GT) and renal function tests (including Scr) will be performed, as well as anteroposterior X-ray examination of the knee joint. Additionally, physicians will inquire about the patient's symptoms based on the questionnaire form for primary and secondary symptoms in Traditional Chinese Medicine (TCM). Subsequently, a physician with a deputy senior professional title or with over ten years of experience in TCM will uniformly conduct TCM syndrome differentiation and typing for the patients. The Central Sensitization Inventory-9 (CSI-9) will be recorded. Record the scales for expected treatment effects and expected side effects.

Experimental group: pain-relieving plaster.

Usage and Dosage: Select the most painful area around the patient's knee joint (Ashi point) or the medial and lateral knee-eye points (EX-LE5) (surface location: located on the extensor surface of the knee joint, in the depression on both sides of the patellar ligament, the medial knee-eye point is called the inner knee-eye point, and the lateral one is called the outer knee-eye point) as the application points. Remove the plastic film, evenly apply the wetting agent in the

small bag to the surface of the medicine core bag, and then directly apply it to the selected application points after wetting, pressing the surrounding adhesive tape. Each plaster is applied for 8 hours, one plaster in the morning every day, with a treatment course of 1 week.

Control group: Flurbiprofen Cataplasms.

Usage and Dosage: The selection method of the application site for the control group is the same as that for the experimental group. Remove the plastic film and directly apply the plaster to the selected application points. Each plaster is applied for 8 hours, one plaster in the morning and one before bedtime every day, with a treatment course of 1 week.

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Pain-Relieving Plaster

Primary outcome(s)

Pain is measured using the pain dimension of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score scale (5 items, totaling 500 points) at baseline, and at weeks 1, 2, and 3

Key secondary outcome(s)

1. Joint stiffness symptoms and function measured using the stiffness and joint functional dimension of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score at baseline, and weeks 1, 2, and 3
2. Quality of life measured using the EuroQol 5-dimension questionnaire (EQ-5D-5L) at baseline, and weeks 1, 2, and 3
3. Degree of knee joint swelling measured using the circumference of the knee joint at baseline, and weeks 1, 2, and 3
4. Functional mobility of the knee joint measured using the knee joint range of motion assessed by a wearable joint range of motion measurement device at baseline, and weeks 1, 2, and 3
5. Safety measured using the laboratory test results (including blood routine, urine routine, and liver and kidney function) at baseline, and weeks 1
6. Safety measured using the adverse event records at weeks 1, 2, and 3
7. Safety measured using the severity of local skin reactions at the application site (assessed by 4 level scale, symptoms include itching, pain, burning sensation, erythema, papules, and blisters) at week 1
8. Patient compliance measured using the drug counting method and follow-up rate method at weeks 1, 2, and 3
9. Application status measured using application time, application quantity, detachment of the plaster, and medication experience at week 1
10. Application status measured using whether to use other treatment methods, and whether to engage in vigorous activities at weeks 1, 2, and 3

Completion date

01/09/2026

Eligibility

Key inclusion criteria

1. Meet the diagnostic criteria for knee osteoarthritis established by the American College of Rheumatology in 1995 (either single or both knees)
2. Age between 40 and 75 years old
3. Experience recurrent knee pain for more than 1 month
4. Kellgren-Lawrence grading scale (K-L grading): Grade II or III
5. Have at least one item with a VAS score ≥ 40 mm among the five items of the WOMAC pain score for the study knee, and all items of the pain score for the contralateral knee osteoarthritis are < 40 mm
6. Provide informed consent, voluntarily participate in the study, and sign the informed consent form

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

40 years

Upper age limit

75 years

Sex

All

Total final enrolment

440

Key exclusion criteria

1. Subjects with clear surgical indications and unsuitable for conservative treatment
2. Subjects with other inflammatory pain diseases in the knee joint, such as rheumatoid arthritis, psoriatic arthritis, gout, villonodular synovitis, septic arthritis, tuberculous arthritis, or osteoarthritis caused by osteomyelitis, bone tumors, and bone tuberculosis. Or those who have undergone joint replacement surgery
3. Subjects allergic to the main components of the test drug, as well as those who have previously experienced skin allergies after using external medications
4. Subjects with skin diseases at and around the application site
5. Subjects with liver function abnormalities, specifically ALT Alanine Aminotransferase. and AST Aspartate Aminotransferase. levels exceeding twice the upper limit of normal, and renal function abnormalities, specifically Scr Serum Creatinine. levels exceeding 1.5 times the upper limit of normal, or subjects deemed by the researcher to have severe primary diseases that preclude their participation in the study. This includes patients with malignant tumors, infectious diseases, and mental illnesses.
6. Subjects who have taken non-steroidal anti-inflammatory drugs orally within 1 week before the screening period, oral hormonal drugs within 1 month, received intra-articular injection

therapy within 3 months, undergone joint surgery within 1 year, or experienced a definite knee injury or open injury within 6 months

7. Women who have a positive blood pregnancy test result during the screening before enrollment; pregnant or lactating women

8. Subjects who, according to the researcher's judgment, have a low probability of enrollment or other circumstances that complicate enrollment, such as those with frequently changing work environments or frequent business trips, which may easily lead to loss of follow-up

9. Subjects who have used Chinese medicine therapies with therapeutic effects on knee osteoarthritis, such as infrared irradiation, cupping, acupuncture, proprietary Chinese medicines, or those participating in other clinical studies

Date of first enrolment

01/10/2024

Date of final enrolment

01/09/2026

Locations

Countries of recruitment

China

Study participating centre

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

No.1 Shuaifuyuan, Dongcheng District

Beijing

China

100730

Study participating centre

Beijing Friendship Hospital Affiliated to Capital Medical University

No. 95 Yong'an Road, Xicheng District

Beijing

China

100050

Study participating centre

Qilu Hospital of Shandong University

No. 107 Wenhua Xi Road, Jinan

Shandong

China

250012

Study participating centre**China-Japan Friendship Hospital**

No. 2 Yinghuayuan Dongjie, Chaoyang District
Beijing
China
100029

Study participating centre**Shu Guang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine**

No. 528 Zhangheng Road, Pudong New Area
Shanghai
China
201203

Study participating centre**The Second Hospital of Lanzhou University**

No. 82 Cuiyingmen, Chengguan District, Lanzhou City
Gansu
China
730030

Study participating centre**Liuzhou People's Hospital**

No. 8 Wenchang Road, Chengzhong District, Liuzhou City
Guangxi
China
545006

Sponsor information**Organisation**

Peking Union Medical College Hospital

ROR

<https://ror.org/04jztag35>

Funder(s)

Funder type

Industry

Funder Name

Tibet Cheezheng Tibetan Medicine Co., Ltd.

Results and Publications

Individual participant data (IPD) sharing plan

The current data sharing plans for this study are unknown and will be available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date